Ntxbio, LLC
Bioreactor systems and proprietary enzymes for on-demand RNA production (mRNA and saRNA)
- Sector
- Biotech
- Headquarters
- NM
- Founded
- 2019
- Latest Form D
- $6K, Jan 2020
- Total capital
- $6K
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $6K
- 1 Form D · last Jan 2020
- 81 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 3 pending · first 2021
- Rank in peer group#4 of 32
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$6K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 32 peers
Line = medianBiotech · Device
- Granted patents#4 · top 13%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Alexander KoglinResearcherExecutive Officer, Director, PromoterLinked by 2 patents
- David R. SeldinDirectorNamed in SEC Form D filings
- Matthew EnnisExecutive OfficerNamed in SEC Form D filings
- Michael HumbertExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Michelle MillerExecutive OfficerNamed in SEC Form D filings
- Stuart SchoenmannExecutive OfficerNamed in SEC Form D filings
Show all 7 people
- Thomas R. NickoloffExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 5- GrantedCell-Free Expression System Having Novel Inorganic Polyphosphate-Based Energy RegenerationUSPTOUS 12,227,778
- GrantedCell-Free Expression System Having Novel Inorganic Polyphosphate-Based Energy RegenerationUSPTOUS 11,136,586
- PendingSystems, Methods And Compositions For Recombinant In Vitro Transcription And Translation Utilizing Thermophilic ProteinsUSPTOApplication 62833555
Show all 5 patent records
- Cell-Free Expression System Having Novel Inorganic Polyphosphate-Based Energy RegenerationFeb 18, 2025 · US 12,227,778Granted
- Cell-Free Expression System Having Novel Inorganic Polyphosphate-Based Energy RegenerationOct 5, 2021 · US 11,136,586Granted
- Systems, Methods And Compositions For Recombinant In Vitro Transcription And Translation Utilizing Thermophilic ProteinsApplication 62833555Pending
- Cell-free Expression System Having Novel Inorganic Polyphosphate-based Energy RegenerationApplication PCTUS2018012121Pending
- Cell-Free Expression System Having Novel Inorganic Polyphosphate-Based Energy RegenerationApplication 62440975Pending
Related companies, and why
- Compvide Inc.Similar federal contract value in Biotech · null in contracts
- Magellan Bioscience Group IncSimilar federal contract value in Biotech · null in contracts
- ExoLytics, Inc.Similar federal contract value in Biotech · null in contracts
- BIOADAPTIVES, INC.Similar federal contract value in Biotech · null in contracts
- NABLA BIO, INC.Similar federal contract value in Biotech · null in contracts
- VersartisSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .